The chemical class designated as TMEM161B Inhibitors encompasses a range of compounds identified for their ability to modulate the activity of the transmembrane protein 161B (TMEM161B). This protein, integral to cellular membranes, plays a crucial role in various cellular processes, although its exact functions are subject to ongoing research. The inhibitors targeting TMEM161B are identified through a comprehensive approach that combines advanced biochemical techniques, structural analysis, and computational biology.
The identification process begins with a detailed understanding of the protein's structure and function. Advanced techniques like X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy are employed to elucidate the three-dimensional structure of TMEM161B. This structural insight is critical as it reveals potential binding sites for inhibitors and helps in understanding the protein's mechanism of action at a molecular level. Once potential binding sites are identified, a library of chemical compounds is screened to find molecules that can bind effectively to these sites. This screening process often uses computational methods like molecular docking and virtual screening, which predict how well each compound in the library fits into the binding site of TMEM161B. These predictions are based on factors like the shape of the compound, its electronic properties, and its potential interactions with the protein.After the initial screening, the most promising compounds are synthesized and subjected to a series of biochemical assays to validate their inhibitory activity. These assays are designed to test the compound's ability to bind to TMEM161B and inhibit its function in a controlled environment, such as in vitro cell cultures. The binding affinity, specificity, and the inhibitory concentration of each compound are meticulously evaluated. This phase is crucial to ensure that the inhibitors are effective and selective for TMEM161B. The compounds that show promising results in these assays are then further analyzed to understand their mechanism of action. This involves studying how the binding of the compound affects the protein's activity and its role in cellular processes. Such studies can involve a range of techniques including fluorescence microscopy, surface plasmon resonance, and isothermal titration calorimetry. Throughout this process, the focus remains on elucidating the molecular interactions between TMEM161B and the inhibitors, aiming to gain a comprehensive understanding of how these compounds modulate the protein's function. This detailed approach ensures that each inhibitor is tailored to interact specifically with TMEM161B, offering precise modulation of its activity. As research progresses, these methods continue to evolve, integrating more sophisticated technologies and analytical techniques, thereby enhancing the efficiency and specificity of the inhibitors in the TMEM161B class.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Could possibly inhibit TMEM161B by affecting kinases in pathways the protein is part of, altering its phosphorylation state. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Could possibly inhibit TMEM161B by altering the dephosphorylation processes in pathways involving the protein. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Could possibly inhibit TMEM161B by affecting the ionic environment and membrane potential, which might influence the protein's function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Could possibly inhibit TMEM161B by impacting gene expression levels of proteins including TMEM161B. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Could possibly inhibit TMEM161B if it interacts with EGFR signaling, as Gefitinib is an EGFR inhibitor. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Could possibly inhibit TMEM161B by affecting cellular growth and proliferation pathways the protein might be a part of. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Could possibly inhibit TMEM161B by affecting calcium signaling which the protein might be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Could possibly inhibit TMEM161B by impacting phosphatidylinositol signaling pathways potentially involving TMEM161B. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $352.00 $1270.00 | 2 | |
Could possibly inhibit TMEM161B by affecting Wnt/β-catenin signaling, a pathway the protein might interact with. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Could possibly inhibit TMEM161B by affecting cytoskeletal dynamics and related signaling. | ||||||